Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Johnson & Johnson in talks to acquire Actelion

Switzerland-based Actelion, a biopharmaceutical company that focuses on drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion in 2015

BS B2B Bureau  |  Basel, Switzerland 

Johnson & Johnson (J&J) on Friday confirmed that it has engaged in preliminary discussions with Swiss biopharmaceutical company Actelion Pharmaceuticals Ltd regarding a potential transaction. Actelion, which sells drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion and a profit of CHF 551.9 million in 2015. Actelion Ltd - a biopharmaceutical company that focuses on the discovery, development and commercialisation of innovative drugs for diseases with significant unmet medical needs - is one of the leading players in the field of pulmonary arterial ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
RECOMMENDED FOR YOU

Johnson & Johnson in talks to acquire Actelion

Switzerland-based Actelion, a biopharmaceutical company that focuses on drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion in 2015

Switzerland-based Actelion, a biopharmaceutical company that focuses on drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion in 2015 Johnson & Johnson (J&J) on Friday confirmed that it has engaged in preliminary discussions with Swiss biopharmaceutical company Actelion Pharmaceuticals Ltd regarding a potential transaction. Actelion, which sells drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion and a profit of CHF 551.9 million in 2015. Actelion Ltd - a biopharmaceutical company that focuses on the discovery, development and commercialisation of innovative drugs for diseases with significant unmet medical needs - is one of the leading players in the field of pulmonary arterial ... image
Business Standard
177 22

Johnson & Johnson in talks to acquire Actelion

Switzerland-based Actelion, a biopharmaceutical company that focuses on drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion in 2015

Johnson & Johnson (J&J) on Friday confirmed that it has engaged in preliminary discussions with Swiss biopharmaceutical company Actelion Pharmaceuticals Ltd regarding a potential transaction. Actelion, which sells drugs for rare diseases, reported revenue of Swiss Francs (CHF) 2.05 billion and a profit of CHF 551.9 million in 2015. Actelion Ltd - a biopharmaceutical company that focuses on the discovery, development and commercialisation of innovative drugs for diseases with significant unmet medical needs - is one of the leading players in the field of pulmonary arterial ...

image
Business Standard
177 22